Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse
PLOS Genetics · 04.03.2024 · 20 (3) · e1011179
DOI: 10.1371/journal.pgen.1011179 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 04.03.2024. Verfasst von Eriks Smagris und 18 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Tarrytown, New York, Unites States of America. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Oximes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Recent human genome-wide association studies have identified common missense variants in MARC1 , p.Ala165Thr and p.Met187Lys, associated with lower hepatic fat, reduction in liver enzymes and protection from most causes of cirrhosis. Using an exome-wide association study we recapitulated earlier MARC1 p.Ala165Thr and p.Met187Lys findings in 540,000 individuals from five ancestry groups. We also discovered novel rare putative loss of function variants in MARC1 with a phenotype similar to MARC1 p.Ala165Thr/p.Met187Lys variants. In vitro studies of recombinant human MARC1 protein revealed Ala165Thr substitution causes protein instability and aberrant localization in hepatic cells, suggesting MARC1 inhibition or deletion may lead to hepatoprotection. Following this hypothesis, we generated Marc1 knockout mice and evaluated the effect of Marc1 deletion on liver phenotype. Unexpectedly, our study found that whole-body Marc1 deficiency in mouse is not protective against hepatic triglyceride accumulation, liver inflammation or fibrosis. In attempts to explain the lack of the observed phenotype, we discovered that Marc1 plays only a minor role in mouse liver while its paralogue Marc2 is the main Marc family enzyme in mice. Our findings highlight the major difference in MARC1 physiological function between human and mouse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Tarrytown, New York, Unites States of America.
ORCID-Profile: Eriks Smagris, Charleen Hunt, Tyler J Greer, Suzanne A Hartford, Jonas B Nielsen
Förderung
- NCATS NIH HHS
- Regeneron Pharmaceuticals
Zitieren
APA
Smagris, E., Shihanian, L. M., Mintah, I. J., Bigdelou, P., Livson, Y., Brown, H., Verweij, N., Hunt, C., Johnson, R. O., Greer, T. J., Hartford, S. A., Hindy, G., Sun, L., Nielsen, J. B., Halasz, G., Lotta, L. A., Murphy, A. J., Sleeman, M. W., & Gusarova, V. (2024). Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse. PLOS Genetics, 20(3), e1011179. https://doi.org/10.1371/journal.pgen.1011179
Vancouver
Smagris E, Shihanian LM, Mintah IJ, Bigdelou P, Livson Y, Brown H, et al. Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse. PLOS Genetics. 2024;20(3):e1011179. doi:10.1371/journal.pgen.1011179
BibTeX
@article{Smagris2024,
author = {Smagris, Eriks and Shihanian, Lisa M and Mintah, Ivory J and Bigdelou, Parnian and Livson, Yuliya and Brown, Heather and Verweij, Niek and Hunt, Charleen and Johnson, Reid O'Brien and Greer, Tyler J and Hartford, Suzanne A and Hindy, George and Sun, Luanluan and Nielsen, Jonas B and Halasz, Gabor and Lotta, Luca A and Murphy, Andrew J and Sleeman, Mark W and Gusarova, Viktoria},
title = {Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse},
journal = {PLOS Genetics},
year = {2024},
volume = {20},
number = {3},
pages = {e1011179},
doi = {10.1371/journal.pgen.1011179}
}
EUVIMED